Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” Joseph M. Terranova, senior managing director for Virtus Investment Partners, said he likes West Pharmaceutical Services, Inc. (NYSE:WST).

Supporting his view, TD Cowen analyst Brendan Smith, on Tuesday, maintained West Pharmaceutical with a Buy rating and raised the price target from $410 to $420.

Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked JPMorgan Chase & Co. (NYSE:JPM).

On the earnings front, JPMorgan, on Tuesday, reported weaker-than-expected third-quarter earnings and revenue. JPMorgan reported adjusted earnings of $5.75 per share, missing the consensus estimate of $5.90. Managed revenue rose 8% year over year to $50.91 billion, below analysts’ expectations of $51.26 billion.

Don’t forget to check out our premarket coverage here

Rob Sechan, CEO of NewEdge Wealth, named Meta Platforms, Inc. (NASDAQ:META) as his final trade.

Lending support to his choice, Truist Securities analyst Youssef Squali, on Tuesday, maintained Meta with a Buy and raised the price target from $763 to $1,000, while Pivotal Research analyst Jeffrey Wlodarczak maintained the stock with a Buy and boosted the price target from $790 to $930.

Shannon Saccocia, Neuberger, recommended iShares U.S. Energy ETF (NYSE:IYE).

Price Action:

• West Pharmaceutical shares gained 1.2% to close at $371.82 on Tuesday.
• JPMorgan fell 0.9% to settle at $331.43 on Tuesday.
• Meta shares rose 2.6% to close at $762.50 during the session.
• iShares U.S. Energy ETF gained 1.9% on Tuesday.

Photo via Shutterstock